Background: Although a number of acute stroke interventions are of proven efficacy, there is uncertainty about their community benefits. We aimed to assess this within a defined population. Methods: Eligibility for tissue plasminogen activator (tPA), aspirin, stroke unit management and neuroprotection were assessed among incident stroke cases within the community-based North East Melbourne Stroke Incidence Study. Results: Among 306,631 people, there were 645 incident strokes managed in hospital. When eligible patients were extrapolated to the Australian population, for every 1,000 cases, 46 (95% CI 17–69) could have been saved from death or dependency with stroke unit management, 6 (95% CI 1–11) by using aspirin, 11 (95% CI 5–17) or 10 (95% CI 3–16) by using tPA at 3 and 6 h, respectively. Conclusions: Although tPA is the most potent intervention, management in stroke units has the greatest population benefit and should be a priority.

Keywords:
Stroke, acute, Tissue plasminogen activator, Community-based stroke units
1.
Adams HP Jr., Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al: Guidelines for Thrombolytic Therapy for Acute Stroke: a supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996;27:1711–1718.
2.
Hacke W, Kaste M, Olsen TS, Orgogozo JM, Bogousslavsky J: European Stroke Initiative: recommendations for stroke management. Organisation of stroke care. J Neurol 2000;247:732–748.
3.
Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, et al: Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999;53(suppl 4):S3–S14.
4.
Wardlaw JM, Sandercock PA, Berge E: Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003;34:1437–1442.
5.
Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al: Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240–1249.
6.
Stroke Unit Trialists’ Collaboration: Organised inpatient (stroke unit) care for stroke: Cochrane Database Syst Rev 2002:CD000197.
7.
Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003;3:9–20.
8.
Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA: Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2000;31:2087–2092.
9.
Sudlow CL, Warlow CP: Comparing stroke incidence worldwide: what makes studies comparable? Stroke 1996;27:550–558.
10.
Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541–553.
11.
Lees KR, Diener HC, Asplund K, Krams M: UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics. Stroke 2003;34:1704–1709.
12.
Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RAL, McNeil JJ, et al: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001;32:2409–2416.
13.
Anderson CS, Jamrozik KD, Burvill PW, Chakera TM, Johnson GA, Stewart-Wynne EG: Ascertaining the true incidence of stroke: experience from the Perth Community Stroke Study, 1989–1990. Med J Aust 1993;158:80–84.
14.
Dunne L, Hugo G, Bamford E, et al: Measuring remoteness: Accessibility/remoteness index of Australia (ARIA). Commonwealth Department of Health and Aged Care 2001. www.health.gov.au/ari/aria.htm.
15.
Ogden K, Cadilhac D, Pearce D, Davis SM, Donnan GA: Australian survey of hospital services for stroke. Cerebrovasc Dis 2001;11(suppl 4):A93.
16.
Stone S: Stroke units. BMJ 2002;325:291–292.
17.
Duffy BK, Phillips PA, Davis SM, Donnan GA, Vedadhaghi ME: Evidence-based care and outcomes of acute stroke managed in hospital specialty units. Med J Aust 2003;178:318–323.
18.
Ardern-Holmes SL, Raman R, Anderson NE, Charleston AJ, Bennett P: Opinion of New Zealand physicians on management of acute ischaemic stroke: results of a national survey. Aust NZ J Med 1999;29:324–330.
19.
Ebrahim S, Redfern J: Stroke Care – A Matter of Chance. Commissioned Report. London, Stroke Association, 1999.
20.
Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE, et al: Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003;178:324–328.
21.
Johnston F, Wardlaw J, Dennis MS, Lewis S, Nimmo G, Lindley RI, et al: Delays in stroke referrals. Lancet 1999;354:47–48.
22.
Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al: Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151–1158.
23.
Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, et al: Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544–1549.
24.
Riopelle RJ, Howse DC, Bolton C, Elson S, Groll DL, Holtom D, et al: Regional access to acute ischemic stroke intervention. Stroke 2001;32:652–655.
25.
Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina PL, et al: Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18–22.
26.
Hankey G, Warlow C: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457–1463.
27.
Evenson KR, Rosamond WD, Morris DL: Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology 2001;20:65–76.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.